Holen Sie sich die Stockscreener-App
8.91
5.61%
-0.53
Handel nachbörslich:
8.91
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Form 144 IMMUNITYBIO For: 1 July By Investing.com - Investing.com Canada
Form 4 Immunitybio Inc For: 1 July By Investing.com - Investing.com Canada
ImmunityBio director Selecky sells $871k in stock - Investing.com
ImmunityBio director Selecky sells $871k in stock By Investing.com - Investing.com Canada
ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares - Stock Titan
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale - Stock Titan
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes - Stocktwits
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales - Stocktwits
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio, Inc.(NasdaqGS: IBRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
IBRX Stock Is Back: Anktiva Now Targets Severe Pneumonia After Clearing Key Checkpoint In Bladder Cancer Trial - Stocktwits
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last? - Yahoo Finance
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
Enterprise value to revenue forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
Enterprise value to revenue forward of ImmunityBio Inc – TRADEGATE:26CA - TradingView
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio, Inc.(NasdaqGS: IBRX) dropped from Russell 3000E Value Benchmark - marketscreener.com
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
2026-06-28 | ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:IBRX | Press Release - Stockhouse
IBRX Stock Enters Heavy Catalyst Phase: Traders Brace For Key Anktiva Decision Amid Trump’s FDA Turmoil - Stocktwits
IBRX Stock Jumps After-Hours: Bulls Cheer ‘Unstoppable’ Global Expansion Amid US Regulatory Heat For Anktiva - Stocktwits
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume - TechStock²
Enterprise value to EBITDA forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
Form 4 Immunitybio Inc For: 26 June By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBIT forward of ImmunityBio Inc – SWB:26CA - TradingView
Director Barry Simon Sells 25,000 Shares of ImmunityBio Inc (IBR - GuruFocus
ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan - Stock Titan
ImmunityBio director Simon Barry J. sells $196,907 of common stock - Investing.com
ImmunityBio director Simon Barry J. sells $196,907 of common stock By Investing.com - Investing.com Nigeria
Price to sales forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
ImmunityBio (NASDAQ:IBRX) rises as Russell index rebalancing and high multiple draw buyers - TechStock²
Price to earnings forward of ImmunityBio Inc – SWB:26CA - TradingView
IBRX Stock Climbs As ANKTIVA Data Spotlight Draws Traders - StocksToTrade
ImmunityBio Confirms Trial Strength For Anktiva In Bladder Cancer - Stocktwits
Price to sales forward of ImmunityBio Inc – SWB:26CA - TradingView
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds - Stocktwits
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio reports progress on bladder cancer filing, shares trade quietly on NASDAQ - Ad-hoc-news.de
Immunitybio Inc (IBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Price to book forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):